Derrick Spell, MD
Hematology & Oncology · Baton Rouge, LANPI 1649291667
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Pfizer at 55.7% of the total. Reporting peaked in 2019 at $1,926 and has fallen 94.2% since, to $112 in 2025. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 119 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Novartis$232
- Merck$219
- Amgen$127
- AstraZeneca$127
- Gilead$127
- plus $765 from 22 others
Across 45 payments — averaging $2983.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$97K
- Pfizer$35K
- Merck$2K
What the payments were for
- Speaking & faculty fees$1,60044%
- Food & beverage$1,98555%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $2,007 |
| Novartis | 15 | $232 |
| Merck | 12 | $219 |
| Amgen | 8 | $127 |
| AstraZeneca | 7 | $127 |
| Gilead | 7 | $127 |
| Tersera Therapeutics LLC | 4 | $110 |
| Daiichi Sankyo Inc. | 3 | $74 |
| Beigene USA, Inc. | 4 | $73 |
| Bristol Myers Squibb | 4 | $71 |
| Eisai Inc. | 3 | $56 |
| Array Biopharma Inc | 3 | $48 |
| CTI Biopharma Corp. | 2 | $36 |
| Deciphera Pharmaceuticals Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Bayer | 1 | $24 |
| EMD Serono, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Eagle Pharmaceuticals, Inc. | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$1,600
How this compares
$3,604 in reported general payments places this provider in the 40th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 67 | $971,443 |
| XareltoRivaroxaban | 43 | $30,092 |
| Tamoxifen Citrate | 847 | $17,984 |
| EliquisApixaban | 21 | $11,187 |
| Anastrozole | 551 | $8,380 |
| Exemestane | 42 | $3,602 |
| Enoxaparin Sodium | 11 | $2,716 |
| Letrozole | 131 | $2,070 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $1,780 |
| Gabapentin | 139 | $1,590 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $1,406 |
| Oxycodone Hcl | 28 | $1,176 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $441 |
| Citalopram HbrCitalopram Hydrobromide | 101 | $285 |
| Ondansetron Hcl | 54 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $16 | $971,44367 claims |
| PfizerEliquis | $2,007 | $11,18721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$2M
- Nakhle SabaBaton Rouge$842K
- Sanjay JunejaBaton Rouge$346K
- Andrew DalovisioBaton Rouge$128K
- Greg BizetteBaton Rouge$32K
- Marshall StaggBaton Rouge$19K
- Christopher McCanlessBaton Rouge$18K
- Georgios ConstantinouBaton Rouge$15K
- Lauren JunejaBaton Rouge$14K
- Victor LinBaton Rouge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.